Results 141 to 150 of about 3,066,509 (354)

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

Targeted poverty alleviation initiatives and corporate sustainable value creation: Determining the role of corporate internal governance control in China. [PDF]

Heliyon, 2023
Bin-Feng C, Zhe L, Mirza SS, Safdar R.
europepmc   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

The SAR analysis of dietary polyphenols and their antagonistic effects on bortezomib at physiological concentrations

Frontiers in Pharmacology
Background: Bortezomib (BTZ), a primary treatment for MM, but its effectiveness can be reduced by interactions with vicinal diol moieties (VDMs) in polyphenols. Despite this, it’s debated whether BTZ therapy necessitates avoiding polyphenol-rich products,
Tran Tran Thi Van, Tran Tran Thi Van, Hsun-Shuo Chang, Hsun-Shuo Chang, Hsun-Shuo Chang, Hsun-Shuo Chang, Ho-Cheng Wu, Ho-Cheng Wu, Chung-Kuang Lu, Chung-Kuang Lu, Hui-Chi Huang, Michal Korinek, Hui-Hua Hsiao, Hui-Hua Hsiao, Hui-Hua Hsiao, Chia-Hung Yen, Chia-Hung Yen, Chia-Hung Yen   +17 more
doaj   +1 more source

How scientists interpret and address funding criteria: value creation and undesirable side effects. [PDF]

Small Bus Econ (Dordr), 2022
O'Kane C, Zhang JA, Haar J, Cunningham JA.   +3 more
europepmc   +1 more source

A New Era of Value Creation – Vertical Value Creation

Procedia CIRP, 2023
Simon Schmidt, Thomas Bauernhansl, Thilo Schlegel, Jörg Siegert   +3 more
openaire   +1 more source

Does Value Creation Drives Growth Illusion? An Evidence from Indonesia Stock Exchange

, 2018
Agus, Imam Ghozali
openalex   +1 more source

The effects of joint-contract functions on PPP project value creation: a mediation model [PDF]

, 2023
Xuewei Li, Jingfeng Yuan, Xuan Liu, Guangqi Wang, Qian-Cheng Wang   +4 more
openalex   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Value Capture from Organizational Advantages and Sustainable Value Creation [PDF]

The impact of firm value capture strategies on the sustainability of the value creation process as a whole has been little discussed in the literature.
Pitelis, Christos
core